vs
Clearfield, Inc.（CLFD）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是Clearfield, Inc.的1.9倍（$65.1M vs $34.3M），MESA LABORATORIES INC净利率更高（5.6% vs -1.8%，领先7.4%），MESA LABORATORIES INC同比增速更快（3.6% vs -3.2%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $-2.4M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -3.5%）
Clearfield, Inc.总部位于美国明尼苏达州明尼阿波利斯市，是一家专注于光纤产品研发生产的企业，其产品主要应用于光纤通信网络建设领域，为通信基础设施部署提供相关硬件支撑。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
CLFD vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.9倍
$34.3M
营收增速更快
MLAB
高出6.8%
-3.2%
净利率更高
MLAB
高出7.4%
-1.8%
自由现金流更多
MLAB
多$20.4M
$-2.4M
两年增速更快
MLAB
近两年复合增速
-3.5%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $34.3M | $65.1M |
| 净利润 | $-614.0K | $3.6M |
| 毛利率 | 33.2% | 64.2% |
| 营业利润率 | -5.3% | 12.2% |
| 净利率 | -1.8% | 5.6% |
| 营收同比 | -3.2% | 3.6% |
| 净利润同比 | 67.8% | 316.6% |
| 每股收益（稀释后） | $-0.04 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLFDMLAB
| Q4 25 | $34.3M | $65.1M | ||
| Q3 25 | $23.4M | $60.7M | ||
| Q2 25 | $49.9M | $59.5M | ||
| Q1 25 | $47.2M | $62.1M | ||
| Q4 24 | $29.7M | $62.8M | ||
| Q3 24 | $5.6M | $57.8M | ||
| Q2 24 | $48.8M | $58.2M | ||
| Q1 24 | $36.9M | $58.9M |
净利润CLFDMLAB
| Q4 25 | $-614.0K | $3.6M | ||
| Q3 25 | $-9.1M | $2.5M | ||
| Q2 25 | $1.6M | $4.7M | ||
| Q1 25 | $1.3M | $-7.1M | ||
| Q4 24 | $-1.9M | $-1.7M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | $-447.0K | $3.4M | ||
| Q1 24 | $-5.9M | $-254.6M |
毛利率CLFDMLAB
| Q4 25 | 33.2% | 64.2% | ||
| Q3 25 | 53.2% | 61.5% | ||
| Q2 25 | 30.5% | 62.0% | ||
| Q1 25 | 30.1% | 61.8% | ||
| Q4 24 | 29.2% | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | 21.9% | 64.0% | ||
| Q1 24 | 7.7% | 62.1% |
营业利润率CLFDMLAB
| Q4 25 | -5.3% | 12.2% | ||
| Q3 25 | 10.3% | 7.8% | ||
| Q2 25 | 3.0% | 5.1% | ||
| Q1 25 | 0.6% | 2.4% | ||
| Q4 24 | -6.9% | 9.2% | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | -4.7% | 9.6% | ||
| Q1 24 | -26.4% | -460.6% |
净利率CLFDMLAB
| Q4 25 | -1.8% | 5.6% | ||
| Q3 25 | -38.8% | 4.1% | ||
| Q2 25 | 3.2% | 8.0% | ||
| Q1 25 | 2.8% | -11.4% | ||
| Q4 24 | -6.4% | -2.7% | ||
| Q3 24 | — | 5.9% | ||
| Q2 24 | -0.9% | 5.8% | ||
| Q1 24 | -16.0% | -432.2% |
每股收益（稀释后）CLFDMLAB
| Q4 25 | $-0.04 | $0.65 | ||
| Q3 25 | $-0.65 | $0.45 | ||
| Q2 25 | $0.11 | $0.85 | ||
| Q1 25 | $0.09 | $-1.30 | ||
| Q4 24 | $-0.13 | $-0.31 | ||
| Q3 24 | — | $0.63 | ||
| Q2 24 | $-0.04 | $0.62 | ||
| Q1 24 | $-0.40 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $96.4M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $249.7M | $186.7M |
| 总资产 | $268.1M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资CLFDMLAB
| Q4 25 | $96.4M | $29.0M | ||
| Q3 25 | $106.0M | $20.4M | ||
| Q2 25 | $117.2M | $21.3M | ||
| Q1 25 | $112.0M | $27.3M | ||
| Q4 24 | $113.0M | $27.3M | ||
| Q3 24 | $129.0M | $24.3M | ||
| Q2 24 | $123.8M | $28.5M | ||
| Q1 24 | $142.9M | $28.2M |
总债务CLFDMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | $2.2M | $73.1M | ||
| Q2 24 | $2.1M | $74.1M | ||
| Q1 24 | — | — |
股东权益CLFDMLAB
| Q4 25 | $249.7M | $186.7M | ||
| Q3 25 | $256.2M | $178.5M | ||
| Q2 25 | $264.5M | $172.5M | ||
| Q1 25 | $265.9M | $159.8M | ||
| Q4 24 | $267.4M | $155.2M | ||
| Q3 24 | $275.8M | $161.5M | ||
| Q2 24 | $274.6M | $150.7M | ||
| Q1 24 | $279.2M | $145.4M |
总资产CLFDMLAB
| Q4 25 | $268.1M | $434.8M | ||
| Q3 25 | $306.2M | $430.4M | ||
| Q2 25 | $314.7M | $435.7M | ||
| Q1 25 | $310.9M | $433.3M | ||
| Q4 24 | $303.2M | $433.3M | ||
| Q3 24 | $315.3M | $454.1M | ||
| Q2 24 | $318.1M | $440.4M | ||
| Q1 24 | $315.4M | $446.8M |
负债/权益比CLFDMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | 0.01× | 0.45× | ||
| Q2 24 | 0.01× | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | $18.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 27.7% |
| 资本支出强度资本支出/营收 | 2.9% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流CLFDMLAB
| Q4 25 | $-1.4M | $18.8M | ||
| Q3 25 | — | $8.2M | ||
| Q2 25 | $7.9M | $1.9M | ||
| Q1 25 | $3.0M | $12.7M | ||
| Q4 24 | $7.2M | $18.1M | ||
| Q3 24 | $22.2M | $5.3M | ||
| Q2 24 | $4.0M | $10.7M | ||
| Q1 24 | $-5.7M | $12.9M |
自由现金流CLFDMLAB
| Q4 25 | $-2.4M | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | $7.5M | $884.0K | ||
| Q1 25 | $654.0K | $11.9M | ||
| Q4 24 | $5.1M | $17.3M | ||
| Q3 24 | $18.2M | $3.5M | ||
| Q2 24 | $2.8M | $9.9M | ||
| Q1 24 | $-7.7M | $12.3M |
自由现金流率CLFDMLAB
| Q4 25 | -7.1% | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | 15.1% | 1.5% | ||
| Q1 25 | 1.4% | 19.2% | ||
| Q4 24 | 17.1% | 27.6% | ||
| Q3 24 | 323.0% | 6.0% | ||
| Q2 24 | 5.8% | 16.9% | ||
| Q1 24 | -20.8% | 21.0% |
资本支出强度CLFDMLAB
| Q4 25 | 2.9% | 1.1% | ||
| Q3 25 | 2.0% | 1.8% | ||
| Q2 25 | 0.8% | 1.7% | ||
| Q1 25 | 5.1% | 1.2% | ||
| Q4 24 | 7.0% | 1.3% | ||
| Q3 24 | 71.4% | 3.1% | ||
| Q2 24 | 2.5% | 1.5% | ||
| Q1 24 | 5.3% | 0.9% |
现金转化率CLFDMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | 4.93× | 0.40× | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLFD
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
